Overview

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Status:
Completed
Trial end date:
2019-10-16
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
Phase:
Phase 4
Details
Lead Sponsor:
AbbVie
Treatments:
Adalimumab